2009-11-16 08:23:21 - ACADIA Pharmaceuticals Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - a new market research report on companiesandmarkets.com

www.companiesandmarkets.com/Summary-Company-Profile/acadia-pharm ..

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson’s disease psychosis. In addition, the Company has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, Inc., and ACP-106 in IND-track development. The Company’s product candidates include Pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark. More from

 

 

Reuters »

ACADIA Pharmaceuticals Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Acadia Pharmaceuticals, Inc. (Acadia) is a biopharmaceutical company, engaged in discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company focuses on developing a portfolio of four advanced product candidates, including Pimavanserin, which is in phase III development for Parkinson’s disease psychosis; and a product candidate in phase II for chronic pain and a product candidate in phase I for glaucoma as well as other drug candidate which are in the preclinical stage of development. It is headquartered at San Diego in California, United States.

The ACADIA Pharmaceuticals Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company’s major recent financial deals.

Scope

- Provides key company information for business intelligence needs
- Gives information on the company’s major recent financial deals including Mergers and Acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.

Reasons to buy

- A quick ""one-stop-shop"" to understand the company.
- Support sales activities by understanding your customers’ businesses.
- Qualify prospective partners and suppliers.
- Understand and respond to your competitors’ business structure, strategy and prospects through.
- Understanding the key deals which have shaped the company.